Peribulbar Triamcinolone for Ocular Myasthenia Gravis

Update Item Information
Identifier 20230312_nanos_posters_213
Title Peribulbar Triamcinolone for Ocular Myasthenia Gravis
Creator Josh Kruger
Affiliation Hadassah-Hebrew University Medical Center
Subject Myasthenia
Description Conventional medical treatment of ocular myasthenia gravis employs an oral/systemic delivery. A recent case series reported successful treatment using peribular dexamethasone (Shi et al, BMC Ophthalmol, 2020). The treatment required up to 6 repeated, weekly injections. I describe the response of three patients to a single dose of peribulbar triamcinolone (40 mg Triescence), a longer-acting corticosteroid.
Date 2023-03-14
Language eng
Format application/pdf
Type Text
Source 2023 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS Annual Meeting 2023: Poster Session I: Orbital and Eyelid Disorders
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Rights Management Copyright 2023. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s666k1wa
Setname ehsl_novel_nam
ID 2335418
Reference URL https://collections.lib.utah.edu/ark:/87278/s666k1wa
Back to Search Results